Supreme Court lifts abortion pill restrictions for now

[ad_1] U.S. Supreme Court Justice Samuel Alito on Friday temporarily blocked lower court rulings that imposed tighter restrictions on the abortion pill mifepristone. U.S. Judge Matthew Kacsmaryk of the U.S. Northern District of Texas suspended the Food and Drug Administration’s approval of mifepristone last week. related investing news The U.S. 5th Circuit Court of Appeals…

Read More

Abortion providers rush to make backup plans as Supreme Court decides whether to keep limits on mifepristone

[ad_1] U.S. abortion pill providers are scrambling to make backup plans as the Supreme Court decides whether to keep restrictions on the key drug mifepristone.  Some in-person clinics in New York, California and Kansas will offer mifepristone for now, but are preparing to provide an alternative abortion pill if a subsequent decision essentially bans the…

Read More

Supreme Court asked to block ruling that threatens access to abortion pill mifepristone

[ad_1] In this photo illustration, packages of Mifepristone tablets are displayed at a family planning clinic on April 13, 2023 in Rockville, Maryland.  Anna Moneymaker | Getty Images The Justice Department and the abortion pill distributor Danco Laboratories on Friday asked the Supreme Court to block an order that threatens access to mifepristone, an escalation…

Read More

‘A hidden gem’: Barclays names 3 stocks to buy in an overlooked area of health care

[ad_1] There’s a global investing opportunity in a corner of health care that is both “significant and underappreciated,” according to Barclays. The segment is clinical nutrition, which the bank defined as an area focused on patients who need specific supplemental nutrition because of chronic health care conditions or because they are unable to eat. Barclays…

Read More

Blocking FDA approval of abortion pill could stifle innovation in the biopharma industry, experts say

[ad_1] A messy legal fight over the Food and Drug Administration’s approval of the abortion pill mifepristone poses risks to the biopharma industry that go beyond the single drug. If a subsequent decision tosses out the pill’s approval, it could potentially stifle innovation in the sector and deter investments in the development of life-changing drugs,…

Read More